<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Pfizer Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/pfizer-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(HUM) Attention Shifts to Jobs &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/04/28/hum-attention-shifts-to-jobs-earnings-preview/99859</link>
		<comments>http://www.stockbloghub.com/2012/04/28/hum-attention-shifts-to-jobs-earnings-preview/99859#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:04:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADM]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[AIG]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[AM]]></category>
		<category><![CDATA[American Greetings Corporation]]></category>
		<category><![CDATA[American International Group Inc]]></category>
		<category><![CDATA[Archer-Daniels-Midland Company]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[Avon Products Inc.]]></category>
		<category><![CDATA[AVP]]></category>
		<category><![CDATA[Cablevision Systems Corporation]]></category>
		<category><![CDATA[CBS]]></category>
		<category><![CDATA[CBS Corporation]]></category>
		<category><![CDATA[CMCSA]]></category>
		<category><![CDATA[Comcast Corporation]]></category>
		<category><![CDATA[CVC]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[EL]]></category>
		<category><![CDATA[Estee Lauder Companies Inc.]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[KFT]]></category>
		<category><![CDATA[Kraft Foods Inc.]]></category>
		<category><![CDATA[L]]></category>
		<category><![CDATA[Loews Corporation]]></category>
		<category><![CDATA[MA]]></category>
		<category><![CDATA[Mastercard Incorporated]]></category>
		<category><![CDATA[Nyse Euronext Inc]]></category>
		<category><![CDATA[NYX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[Time Warner Inc.]]></category>
		<category><![CDATA[TWX]]></category>
		<category><![CDATA[V]]></category>
		<category><![CDATA[VIAB]]></category>
		<category><![CDATA[Viacom]]></category>
		<category><![CDATA[Visa Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99859</guid>
		<description><![CDATA[Earnings Preview – Week of April 30th The focus this week will be on the labor market, with the April non-farm payroll report coming out on Friday. Many will be hoping that this report will provide confirmation that last month’s disappointment was just a one-off event and the positive trend line of the preceding months is still in place. Jobs aside, we are still in the midst of the first quarter 2012 reporting season, though we have crossed the mid-point of the cycle with about 60% of the results already in. With another 124 S&#38;P 500 companies reporting results in the coming week, we will have results from roughly 84% of the companies by the end of this week. The first quarter earnings season has turned out to be much ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/hum-attention-shifts-to-jobs-earnings-preview/99859/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis&#8217; Cancer Drug Afinitor Shows Promise for Breast Cancer</title>
		<link>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414</link>
		<comments>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414#comments</comments>
		<pubDate>Mon, 12 Dec 2011 22:12:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88414</guid>
		<description><![CDATA[Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion. Afinitor is not yet approved for the treatment of breast cancer. The pivotal late-stage study (BOLERO-2) evaluated the use of Afinitor in combination with Pfizer’s (PFE) Aromasin (a hormonal therapy) in postmenopausal women with metastatic breast cancer whose disease has progressed, despite treatment with hormonal therapies like Novartis’ Femara or AstraZeneca’s (AZN) Arimidex. The long-term data showed that Afinitor plus Aromasin expanded progression-free survival (PFS), or time, without causing tumor growth in patients, by more than two times versus Aromasin alone. Treatment with Afinitor improved the PFS to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor</title>
		<link>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086</link>
		<comments>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086#comments</comments>
		<pubDate>Tue, 06 Dec 2011 17:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88086</guid>
		<description><![CDATA[November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator and its loss of exclusivity could very well represent the biggest generic opportunity in recent times. Lipitor sales came in at $10.7 billion in 2010 with sales for the first nine months of 2011 coming in at $7.6 billion. Pfizer Goes Aggressive Typically, whenever a branded drug loses exclusivity, it witnesses a rapid erosion in sales with the entry of generic versions. However, Pfizer is trying to turn the tide in its favor by adopting several steps to minimize the impact of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071</link>
		<comments>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071#comments</comments>
		<pubDate>Tue, 06 Dec 2011 00:54:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88071</guid>
		<description><![CDATA[Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food &#38; Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and Abbott Labs&#8216; (ABT) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan’s already strong portfolio of ARV’s in India. In a separate development, Mylan announced that Warner Chilcott Company (WCRX) filed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Novartis</title>
		<link>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474</link>
		<comments>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:41:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87474</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic version of Vivelle-Dot on December 16, 2013, or earlier under certain circumstances. Mylan was the first to file an abbreviated new drug application (ANDA) with the US Food &#38; Drug Administration (FDA) to market the generic version of the drug. Accordingly, Mylan will enjoy an exclusivity period of 180 days when it will be the sole company to market the generic. The deal is subject to review by the US Department of Justice and the Federal Trade Commission. Earlier this month, Mylan entered into an agreement with Pfizer, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692</link>
		<comments>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692#comments</comments>
		<pubDate>Wed, 21 Sep 2011 14:56:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83692</guid>
		<description><![CDATA[We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include: gastrointestinal, cardiovascular, respiratory and inflammation, oncology, neuroscience, infection and other. The company’s key products include Crestor (cholesterol management); Nexium (acid reflux); Seroquel (schizophrenia and bipolar mania); Atacand (hypertension and symptomatic heart failure), Arimidex (breast cancer), Zoladex (prostate and breast cancer) and Symbicort (asthma). We are impressed by the performance of lead drug Crestor which is primarily responsible for AstraZeneca being one of the leading players in the global cardiovascular market. The US launch of Brilinta (ticagrelor) for the reduction of the rate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Drug Cleared in European Union for SEGA</title>
		<link>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127</link>
		<comments>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:12:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83127</guid>
		<description><![CDATA[Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication be available in this region for the treatment of this challenging disease. Votubia is already marketed in the US under the trade name Afinitor for the disease. It is also approved in Switzerland, Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Earlier in June this year, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Votubia for the indication. The recommendation was based on data from a mid-stage study, which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug Presents Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159</link>
		<comments>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159#comments</comments>
		<pubDate>Tue, 20 Sep 2011 18:50:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83159</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently presented positive data from a late-stage trial on its erectile dysfunction (ED) candidate, avanafil, at the 47th European Association for the Study of Diabetes Annual Meeting. The REVIEW-Diabetes study (TA-302), which enrolled 390 patients with type I and type II diabetes, demonstrated that patients receiving avanafil achieved significant improvement in erectile function. The data reported that patients dosed with avanafil showed improvement in the percentage of successful intercourse attempts, regardless of diabetes classification (type I or II), duration of diabetes, or baseline ED severity. Further, successful intercourse was achieved in some patients within 15 minutes of taking avanafil. Moreover, some patients experienced successful intercourse more than six hours after dosing. On average, the patients who enrolled for the study were 58 years old and had a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell</title>
		<link>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032</link>
		<comments>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:49:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83032</guid>
		<description><![CDATA[We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active metabolite of the cancer drug, irinotecan, for the treatment of metastatic colorectal cancer (mCRC). Enzon decided to halt development as the company intends to focus its resources on other areas with nearer-term commercial potential. The discontinuation of development of PEG-SN38 for mCRC is a disappointment, leaving the company with just one clinical program in mid-stage development (PEG-SN38 for metastatic breast cancer) and all others in early stages of development. The company’s pipeline candidates include PEG-SN38, hypoxia-inducible factor1 (HIF-1) alpha, survivin antagonists and multiple messenger RNA (mRNA) antagonists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258</link>
		<comments>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258#comments</comments>
		<pubDate>Wed, 14 Sep 2011 16:41:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82258</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional risk factor for stroke. The cardiac rhythm disorder is referred to as atrial fibrillation (AF). Bristol-Myers and Pfizer presented detailed data from the study at the European Society of Cardiology. Topline results were presented in June 2011. Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US. Data from the randomized, double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin in reducing the risk of stroke or systemic embolism. Patients treated with Eliquis were 21% less likely ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655</link>
		<comments>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655#comments</comments>
		<pubDate>Sun, 11 Sep 2011 19:54:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82655</guid>
		<description><![CDATA[Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based on the RADIANT-3 trial which demonstrated that Afinitor led to a statistically significant improvement in progression-free survival versus placebo. The number of months of survival without the disease progressing was 11 months for a patient treated with Afinitor versus 4.6 months for a patient on placebo. Afinitor is currently marketed for the treatment of advanced renal cell carcinoma (kidney cancer) after an anti-VEGF therapy like Roche’s (RHHBY) Avastin, Pfizer’s (PFE) Sutent or Onyx Pharmaceuticals’(ONXX) Nexavar in the US and EU. In June this year, the Committee for Medicinal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SCR) Simcere Drug Cleared in China</title>
		<link>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262</link>
		<comments>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262#comments</comments>
		<pubDate>Thu, 01 Sep 2011 17:26:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[SCR]]></category>
		<category><![CDATA[Simcere Pharmaceutical Group.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82262</guid>
		<description><![CDATA[Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first Iguratimod drug to hit the global market and will be used mainly to treat patients suffering from active RA. Iguratimod refers to a new disease-modifying, anti-rheumatoid therapy and belongs to the category of Disease Modifying Anti-rheumatic Drugs (DMARDs). The approval of Iremod by the Chinese regulatory authorities will not only boost Simcere’s top line but also widen the treatment options for patients suffering from the dreaded disease, whose incidence is on the rise. Iremod will operate in a highly lucrative market and will compete with players like Bristol-Myers (BMY), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALL) Company News for August 30, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/30/all-company-news-for-august-30-2011-corporate-summary/82281</link>
		<comments>http://www.stockbloghub.com/2011/08/30/all-company-news-for-august-30-2011-corporate-summary/82281#comments</comments>
		<pubDate>Tue, 30 Aug 2011 18:53:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Barnes Group Inc.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Crosshair Exploration & Mining Corporation]]></category>
		<category><![CDATA[CXZ]]></category>
		<category><![CDATA[JNY]]></category>
		<category><![CDATA[Jones Apparel Group Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Samson Oil & Gas Limited]]></category>
		<category><![CDATA[SSN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82281</guid>
		<description><![CDATA[•    Bank of America (NYSE:BAC) shares increased 8.12% to close at $8.39 after the bank disclosed it would be selling half of its holdings to China Construction Bank Corp in order to raise capital •    Share prices of insurer The Allstate Corp. (NYSE:ALL) advanced 8.50% to close at $26.30 after estimates showed property damage from Hurricane Irene was relatively lower •    Crosshair Exploration &#38; Mining (AMEX:CXZ) has told Australian American Mining Corp. Limited that it wishes to acquire its United States uranium assets. As per the proposal, AusAm will get US$12.85 million payable in Crosshair shares •    Share prices of Samson Oil &#38; Gas (AMEX:SSN) gained 3.83% after exploration company was awarded 956 net acres of leasehold land on conditional basis by the University of Wyoming •    Pharma giants Bristol-Myers ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/all-company-news-for-august-30-2011-corporate-summary/82281/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113</link>
		<comments>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:29:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82113</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on AmerisourceBergen Corporation (ABC) with a target price of $40.00. Over the last several years, the company has been benefiting from the growth of the pharmaceutical industry in the US. We believe AmerisourceBergen should continue to benefit from growth in the pharmaceutical industry, which is driven by several factors like aging population, increased use of generics, introduction of new treatments, increased use of drug therapies and favorable legislative developments. The aforesaid points are continually helping the company, which increased its 2011 earnings guidance range following the release of the third quarter fiscal 2011 financial results. AmerisourceBergen now expects 2011 earnings to lie in the range of $2.52 &#8211; $2.56 per share (previous guidance: $2.41 &#8211; $2.49). We expect fiscal 2011 earnings to increase almost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145</link>
		<comments>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:26:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82145</guid>
		<description><![CDATA[We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks Consensus Estimate by a penny and the year-ago earnings by 18 cents. Earnings were bolstered by higher revenues. Revenues for the quarter climbed 24% to $1.08 billion, beating the Zacks Consensus Estimate of $992 million. Revenues went up mainly due to increased generic and branded drug sales. Following the better-than-expected second quarter results, Watson Pharma increased its 2011 earning guidance range to $4.25-$4.50 per share from $3.95-$4.20. We note that the company enjoys a strong position in the generic pharmaceutical market. At the end of 2010, Watson Pharma had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823</link>
		<comments>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823#comments</comments>
		<pubDate>Thu, 25 Aug 2011 16:48:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81823</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents and also beat the year-ago earnings 37 cents. Earnings growth was driven by an increase in generics revenue and improved gross margins. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 17% to $1.44 billion in the second quarter of 2011 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in other markets like Asia-Pacific and North America. Mylan is one of the leading players in the generics market. A large number of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BK) Company News for August 15, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/16/bk-company-news-for-august-15-2011-corporate-summary/81326</link>
		<comments>http://www.stockbloghub.com/2011/08/16/bk-company-news-for-august-15-2011-corporate-summary/81326#comments</comments>
		<pubDate>Tue, 16 Aug 2011 18:00:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BP]]></category>
		<category><![CDATA[BP plc]]></category>
		<category><![CDATA[DDS]]></category>
		<category><![CDATA[DeVry Inc.]]></category>
		<category><![CDATA[Dillard's Inc.]]></category>
		<category><![CDATA[DV]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[J. C. Penney Company Inc]]></category>
		<category><![CDATA[JCP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[RODM]]></category>
		<category><![CDATA[Rodman & Renshaw Capital Group Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[TISA]]></category>
		<category><![CDATA[Top Image Systems Limited]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81326</guid>
		<description><![CDATA[•    Dillard&#8217;s Inc. (NYSE:DDS) posted strong second-quarter 2011 earnings of $0.30 per share, outpacing the Zacks Consensus Estimate of $0.19 per share and prior-year quarter earnings of $0.03 per share •    J. C. Penney Company, Inc. (NYSE:JCP) posted second-quarter 2011 earnings of $0.07 a share that came in a penny ahead of the Zacks Consensus Estimate as well as the prior-year quarter’s earnings •    Attorney generals in Virginia and Florida accused The Bank of New York Mellon Corporation (NYSE:BK) of employing a currency-trading method that cheated pension funds and filed a civil suit against the bank •    According to reports, Pfizer Inc. (NYSE:PFE) informed U.S. authorities about &#8220;potentially improper payments&#8221; it made outside the United States •    Wells Fargo &#38; Company (NYSE:WFC) upgraded Polaris Industries, Inc. (NYSE:PII) to “Outperform” from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/bk-company-news-for-august-15-2011-corporate-summary/81326/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ONXX) Onyx Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354</link>
		<comments>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354#comments</comments>
		<pubDate>Tue, 16 Aug 2011 18:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81354</guid>
		<description><![CDATA[We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved sales of the company’s only marketed drug, Nexavar (sorafenib) for cancer, which came in at $245.7 million (up 4% year-over-year) during the quarter, Onyx Pharma’s revenues experienced a 1.2% decline, amounting to $68.0 million. Earnings were further reduced as a result of higher-than-expected operating expenses. While research and development (R&#38;D) spend went up 16.2% to $50.3 million, selling, general and administrative (SG&#38;A) expenses shot up 43.6% to $38.2 million. Increased expenses for the development of carfilzomib led to higher R&#38;D spend and an increase in employee headcount and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Stock Market News for August 16, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/08/16/aa-stock-market-news-for-august-16-2011-market-news/81400</link>
		<comments>http://www.stockbloghub.com/2011/08/16/aa-stock-market-news-for-august-16-2011-market-news/81400#comments</comments>
		<pubDate>Tue, 16 Aug 2011 17:01:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RIG]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>
		<category><![CDATA[Time Warner Cable Inc.]]></category>
		<category><![CDATA[Transocean Limited]]></category>
		<category><![CDATA[TWC]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81400</guid>
		<description><![CDATA[In what is being termed as the return of “Merger Monday”, an acquisition spree gave a boost to markets which posted its longest rally since early July. Additionally, positive economic news from Japan also brought joy to the markets and helped the Dow record its best three-day point gains since November 2008. The Dow Jones Industrial Average (DJIA) jumped 213 points or 1.9% to settle at 11,482.90. The Standard &#38; Poor 500 (S&#38;P500) gained 2.2% and closed the day at 1,204.49. The Nasdaq Composite Index surged 1.9% to finish the day at 2,555.20. On the New York Stock Exchange, consolidated volumes were at 4.5 billion shares, marginally ahead of last year’s average of 4.3 billion shares. However, the volumes were significantly lower than last week’s record volumes that went past ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/aa-stock-market-news-for-august-16-2011-market-news/81400/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Loss Narrowed Due To Lower Spend</title>
		<link>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947</link>
		<comments>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[OC]]></category>
		<category><![CDATA[Owens Corning]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80947</guid>
		<description><![CDATA[Vivus Inc. (VVUS) posted adjusted loss of 14 cents per share during the second quarter of fiscal 2011, in line with the Zacks Consensus Estimate. However, the loss was narrower than the year-ago loss of 27 cents per share. Lower operating expenses led to the narrower loss. The company did not record any revenues during the quarter, similar to the prior-year quarter. The Zacks Consensus Estimate for the quarter was $1 million. Quarterly Details During the quarter, research and development (R&#38;D) expenses decreased 18.7% to $11.0 million. Moreover, general and administrative expenses amounted to $5.3 million, reflecting a decline of 21.4%. Vivus experienced reduced R&#38;D spends during the reported quarter, as both Qnexa and avanafil have completed their clinical studies and have been filed for regulatory approval. Pipeline Update In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Reports Solid Quarter</title>
		<link>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:53:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80092</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the quarter decreased 2% to $0.52 per share. The healthcare reform enacted in 2010 negatively impacted earnings in the reported quarter by $0.03. Net sales in the reported quarter climbed 14% to $5.4 billion. Foreign exchange positively impacted sales in the quarter by 4%. Revenues also surpassed the Zacks Consensus Estimate of $5.0 billion, driven by the impressive showing of Bristol-Myers’ lead drugs including blood thinner Plavix. US net sales in the quarter climbed 15% to $3.6 billion. Sales in international markets increased 13% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BGC) Company News for August 3, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/03/bgc-company-news-for-august-3-2011-corporate-summary/80511</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bgc-company-news-for-august-3-2011-corporate-summary/80511#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:33:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Industrial Electrical Equipment]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[BGC]]></category>
		<category><![CDATA[Foster Wheeler AG]]></category>
		<category><![CDATA[FWLT]]></category>
		<category><![CDATA[General Cable Corporation]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Herbalife Limited]]></category>
		<category><![CDATA[HLF]]></category>
		<category><![CDATA[II-VI Inc]]></category>
		<category><![CDATA[IIVI]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[Westlake Chemical Corporation]]></category>
		<category><![CDATA[WLK]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80511</guid>
		<description><![CDATA[•    Westlake Chemical Corporation (NYSE:WLK) posted Q2 EPS of $1.21, beating analysts’ estimates of $1.19 per share. Revenues rose 13% year-over-year to $925.0 million •    Engineering company Foster Wheeler AG’s (NASDAQ:FWLT) shares rose 2.12% to close at $27.02 after the company posted second-quarter earnings that came in above the Street&#8217;s expectations •    Share prices of Herbalife Ltd. (NYSE:HLF) increased 5.69% after the nutritional-supplement seller forecasted third-quarter earnings beating analysts’ estimates •    Pfizer (NYSE:PFE) reported adjusted Q2 EPS of $0.60, marginally ahead of the Zacks Consensus Estimate of $0.59 per share. Revenues for the quarter fell 1% to $17.0 billion, in line with the Zacks Consensus Estimate •    General Cable Corp.’s  (NYSE:BGC) share prices declined by 17.67% after the wire maker&#8217;s second quarter profit and revenue figures came in behind estimates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bgc-company-news-for-august-3-2011-corporate-summary/80511/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Earns FDA Approval for Generic</title>
		<link>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064</link>
		<comments>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064#comments</comments>
		<pubDate>Thu, 14 Jul 2011 18:48:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79064</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline plc (GSK) for preventing deep vein thrombosis (DVT) in adults who are undergoing hip fracture, hip replacement, or knee replacement surgery. Dr. Reddy’s received final approval from the FDA for the 2.5 mg/ 0.5 mL, 5.0 mg/ 0.4 mL, 7.5 mg/ 0.6 mL and 10 mg/ 0.8 mL doses of fondaparinux sodium injection. Dr. Reddy’s will be manufacturing the generic version under license using a patented process that is developed by Australia based Alchemia Limited. The current approval comes close on the heels of the US launch of the generic version of Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KCI) Kinetic Concepts Aquired by Apax Partners and Two Canadian Pension Funds</title>
		<link>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075</link>
		<comments>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:43:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AHS]]></category>
		<category><![CDATA[AMN Healthcare Services Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Total System Services Inc]]></category>
		<category><![CDATA[TSS]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79075</guid>
		<description><![CDATA[Private equity firm Apax Partners and two Canadian pension funds are set to acquire leading medical technology company Kinetic Concepts (KCI). The deal, including Kinetic&#8217;s outstanding debt, is valued at approximately $6.3 billion. As an independent global partnership, Apax exclusively focuses on long-term investment in growth companies. The acquisition of Kinetic is part of Apax’s intention to support deals in the financial &#38; business services, healthcare, media, retail &#38; consumer and technology sectors. However, probably its budget doesn’t permit such a big acquisition at this point, so Apax teamed up with the Canada Pension Plan Investment Board (CPPIB) and the Public Sector Pension Investment Board (PSP Investments) to get the deal done. As per the terms of the agreement, Kinetic’s shareholders will receive $68.50 in cash for each share of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Presents Afinitor Data</title>
		<link>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847</link>
		<comments>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847#comments</comments>
		<pubDate>Tue, 12 Jul 2011 16:58:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78847</guid>
		<description><![CDATA[Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety and effectiveness of the drug compared to placebo for treating patients with subependymal giant cell astrocytomas (SEGAs) coupled with tuberous sclerosis (TS). Results from the study were presented at the International tuberous sclerosis complex (TSC) Research Conference in the US. The study revealed that treatment with Afinitor caused a 50% or more reduction in SEGA tumor size in 35% of the patients. However, no such reduction was observed in the placebo arm. SEGA refers to a benign brain tumor associated with tuberous sclerosis. TSC, which is associated with multiple disorders such as seizures, swelling in the brain, developmental delays and skin lesions, affects approximately one ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ADP) Stock Market News for July 8, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/07/08/adp-stock-market-news-for-july-8-2011-market-news/78660</link>
		<comments>http://www.stockbloghub.com/2011/07/08/adp-stock-market-news-for-july-8-2011-market-news/78660#comments</comments>
		<pubDate>Fri, 08 Jul 2011 17:37:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Business Software & Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[BP]]></category>
		<category><![CDATA[BP plc]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CLF]]></category>
		<category><![CDATA[Cliffs Natural Resources Inc.]]></category>
		<category><![CDATA[COST]]></category>
		<category><![CDATA[Costco Wholesale Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Energy Select Sector SPDR]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[General Moly Inc]]></category>
		<category><![CDATA[GMO]]></category>
		<category><![CDATA[HES]]></category>
		<category><![CDATA[Hess Corporation]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[PBR]]></category>
		<category><![CDATA[Petroleo Brasileiro]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Saks Incorporated]]></category>
		<category><![CDATA[SKS]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[XLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78660</guid>
		<description><![CDATA[On Thursday, positive jobs and retail reports lifted investor sentiment and subsequently boosted the benchmarks which edged closer to 2011 highs. Nonetheless, volumes remained tight as investors anxiously await crucial non-farm payroll data from the government. The Dow Jones Industrial Average (DJIA) gained 0.7% to finish at 12,719.49. The Standard &#38; Poor 500 (S&#38;P 500) surged 1.1% to settle at 1,353.22. The Nasdaq Composite Index was up 1.4% to close at 2,872.66. Volumes remained tight as on the York Stock Exchange, AMEX and Nasdaq, only 6.69 billion shares were traded compared with last year&#8217;s daily average of 8.47 billion. On the NYSE, only 2.2 billion shares were traded and for four advancing stocks, only one declined. The Dow has now gained 6.6% over its last eight trading days and is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/08/adp-stock-market-news-for-july-8-2011-market-news/78660/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG&#8217;s Afinitor Impresses Again</title>
		<link>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554</link>
		<comments>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554#comments</comments>
		<pubDate>Thu, 07 Jul 2011 17:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78554</guid>
		<description><![CDATA[It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week for the treatment of subependymal giant cell astrocytomas (SEGA), the drug impressed again this week with positive interim results from a pivotal late-stage trial (BOLERO-2). BOLERO-2 evaluated Afinitor in combination with exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor-positive locally-advanced breast cancer, whose disease progressed, despite treatment with the nonsteroidal aromatase inhibitors letrozole or anastrozole. The trial results demonstrated that patients with advanced breast cancer who were dosed Afinitor in combination with exemestane, experienced significantly extended progression-free survival (PFS), as compared to patients who received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351</link>
		<comments>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:16:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78351</guid>
		<description><![CDATA[We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share. We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first drug, antibiotic Dificid, for the treatment of clostridium difficile-associated diarrhea (CDAD), highly encouraging. CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid is the only drug which has shown superiority over ViroPharma’s (VPHM) Vancocin &#8211; the only other FDA approved antibiotic for the treatment of clostridium difficile infection &#8211; in sustaining clinical response for CDAD. The superior recurring benefits of Dificid over Vancocin will be included ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals&#8217; Back Pain Drug Disappoints</title>
		<link>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262</link>
		<comments>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:04:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78262</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently suffered a pipeline setback with its candidate axomadol performing disappointingly in a mid-stage trial (n=236). Top line results from the study revealed that Endo Pharma’s candidate failed to meet the predetermined end points. The randomized, double blind, two-arm, placebo-controlled study evaluated the candidate in patients suffering from moderate-to-severe chronic low back pain. Endo Pharma in-licensed the US and Canadian development and marketing rights of axomadol from Grunenthal in 2009. The 4-week study evaluated the candidate at doses ranging from 100 mg/day to 300 mg/day. The maintenance phase of the study was 12 weeks. The main goal was a change in the average intensity of pain measured by a numerical rating scale from baseline to the final week of treatment for all patients who were treated with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAC) Stock Market News for July 1, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/07/01/bac-stock-market-news-for-july-1-2011-market-news/78202</link>
		<comments>http://www.stockbloghub.com/2011/07/01/bac-stock-market-news-for-july-1-2011-market-news/78202#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:41:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[Joy Global Inc.]]></category>
		<category><![CDATA[JOYG]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[NetApp Inc.]]></category>
		<category><![CDATA[NTAP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[Valero Energy Corporation]]></category>
		<category><![CDATA[VLO]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78202</guid>
		<description><![CDATA[The Street ended one of its most volatile quarters, with positive economic reports and a temporary solution to the Greece debt crisis lifting the benchmarks to post their biggest four-day rally since September. The technology sector and energy sector lifted the mood further and investors are now hoping for a robust forthcoming earnings season. The Dow Jones Industrial Average (DJIA) moved up 1.3% to settle at 12,414.34. The Standard &#38; Poor 500 (S&#38;P 500) gained 1.0% to close at 1,320.64. The tech-laden Nasdaq Composite Index surged 1.2% to finish the day at 2,773.52. On the New York Stock Exchange, AMEX and Nasdaq, consolidated volumes were 6.88 billion compared to the year&#8217;s daily average of 7.56 billion. For every 11 stocks that climbed higher on the NYSE, 4 stocks declined. Among ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/bac-stock-market-news-for-july-1-2011-market-news/78202/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer Drug Accepted for Standard FDA Review</title>
		<link>http://www.stockbloghub.com/2011/06/30/pfe-pfizer-drug-accepted-for-standard-fda-review/78034</link>
		<comments>http://www.stockbloghub.com/2011/06/30/pfe-pfizer-drug-accepted-for-standard-fda-review/78034#comments</comments>
		<pubDate>Thu, 30 Jun 2011 20:38:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RCC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78034</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently announced that its regulatory application for oncology candidate, axitinib has been accepted for standard review by the US Food and Drug Administration (FDA). The company is seeking approval for the treatment of patients with advanced renal cell carcinoma (RCC). The regulatory application was based on data from the phase III AXIS 1032 study which compared axitinib with Onyx Pharmaceuticals/Bayer’s (ONXX/BAYRY) Nexavar (sorafenib). Earlier this month, the European Medicines Agency (EMA) also accepted Pfizer’s regulatory filing for axitinib. Pfizer is seeking EU approval for the use of axitinib in treatment-failed patients with advanced renal cell carcinoma. The approval of axitinib would provide advanced renal cell carcinoma patients, especially previously-treated patients, with an additional treatment option. According to Pfizer, kidney cancer is diagnosed in about 210,000 people every ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/pfe-pfizer-drug-accepted-for-standard-fda-review/78034/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG Afinitor Backed in EU</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:55:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77906</guid>
		<description><![CDATA[Novartis AG (NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), in the European Union. The European Commission is expected to give its decision within the next three months. The drug will be marketed in the EU in the trade name of Votubia and will be the first medicine in the region for the treatment of this challenging disease, if approved. It is already marketed in the US as Afinitor for the disease. It is also approved in Switzerland Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications</title>
		<link>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565</link>
		<comments>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:11:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77565</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline plc’s (GSK) Avodart, indicated for the treatment of benign prostatic hyperplasia (BPH), and Novartis AG’s (NVS) Pataday 0.2%, indicated for the treatment of ocular itching that is associated with allergic conjunctivitis. In response, Glaxo filed a lawsuit against Watson Pharma in the United States District Court for the District of Delaware, and Alcon filed a lawsuit against Watson Pharma in the United States District Court for the Southern District of Indiana. Since both companies filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma’s generic Avodart and generic Pataday until November 17, 2013 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical to Buy Pfizer Plant</title>
		<link>http://www.stockbloghub.com/2011/06/29/bmrn-biomarin-pharmaceutical-to-buy-pfizer-plant/77641</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bmrn-biomarin-pharmaceutical-to-buy-pfizer-plant/77641#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:04:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77641</guid>
		<description><![CDATA[BioMarin Pharmaceutical Inc. (BMRN) recently announced that it will acquire an integrated biologics manufacturing plant from pharma giant Pfizer Inc. (PFE) which will expand its manufacturing capacity to manage its proliferating product portfolio and its maturing pipeline. The plant, for which BioMarin will pay $48.5 million, is located in Shanbally, Cork, Ireland and is spread across 133,000 square feet. The purchase price is almost five times less than the cost of building a new facility. BioMarin is expected to close the deal in the third quarter of 2011. Moreover, BioMarin will have to spend approximately $4 million annually to maintain the facility. The current manufacturing facilities have the capacity to manufacture protein products worth roughly $1 billion in revenue. With a maturing pipeline, the company will need additional resources to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bmrn-biomarin-pharmaceutical-to-buy-pfizer-plant/77641/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGNC) Company News for June 28, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/28/agnc-company-news-for-june-28-2011-corporate-summary/77704</link>
		<comments>http://www.stockbloghub.com/2011/06/28/agnc-company-news-for-june-28-2011-corporate-summary/77704#comments</comments>
		<pubDate>Tue, 28 Jun 2011 18:32:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[AGNC]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[American Capital Agency Corporation]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[DreamWorks Animation SKG Inc.]]></category>
		<category><![CDATA[DWA]]></category>
		<category><![CDATA[EXPD]]></category>
		<category><![CDATA[Expeditors International of Washington Inc]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[LDK]]></category>
		<category><![CDATA[LDK Solar CompanyLimited]]></category>
		<category><![CDATA[Molex Inc.]]></category>
		<category><![CDATA[MOLX]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[UFPI]]></category>
		<category><![CDATA[Universal Forest Products Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77704</guid>
		<description><![CDATA[•    Shares of online company Amazon.com, Inc. (NASDAQ:AMZN) gained 4.52% after analysts at Morgan Stanley (NYSE:MS) opined that the company&#8217;s fourth quarter profits and margins will outperform the Street&#8217;s expectations •    Share prices of Icagen, Inc. (NASDAQ:ICGN) zoomed up 163.76% to close at $6.33 after Pfizer Inc. (NYSE:PFE) disclosed that the drug manufacturer is planning to enter into a strategic alliance with Icagen •    The Board of directors of LDK Solar Co (NYSE:LDK) has authorized the repurchase of up to $110 million of American Depositary Shares •    Share prices of Universal Forest Products, Inc. (NASDAQ:UFPI) shed 9.71% after the company said it will initiate a cost-cutting program because of declining sales this year •    Fitch Ratings downgraded the credit rating of Best Buy Co (NYSE:BBY) due to  lower stores sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/agnc-company-news-for-june-28-2011-corporate-summary/77704/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Pain Therapeutics Get Bad News for Remoxy</title>
		<link>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578</link>
		<comments>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77578</guid>
		<description><![CDATA[The US Food and Drug Administration recently dealt a blow to Pfizer (PFE) and Pain Therapeutics, Inc. (PTIE) by issuing a second complete response letter (CRL) for their opioid candidate, Remoxy. Remoxy became a part of Pfizer’s pipeline following its acquisition of King Pharmaceuticals earlier this year. Remoxy has been developed, using Durect Corporation’s (DRRX) ORADUR technology, for moderate to severe pain that requires continuous, around-the-clock opioid treatment for an extended period of time. The CRL is a major setback for Pain Therapeutics and Durect Corp. While Pain Therapeutics’ shares dropped more than 40% on the news, Durect’s shares were down 31%. Second CRL for Remoxy Remoxy’s regulatory path has not been smooth with the candidate receiving a second CRL from the FDA. King Pharma had initially submitted the Remoxy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Announces FDA Action Date</title>
		<link>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598</link>
		<comments>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:46:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77598</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently announced that the US Food and Drug Administration (FDA) has issued a new action date for the new formulation of painkiller Opana ER. The FDA stated that it will review Endo Pharma’s response to the agency’s complete response letter (CRL) by December 13, 2011. The new formulation of Opana ER is designed to resist attempts of crushing, breaking, pulverizing or making a powder of the product. The candidate aims to bring relief to patients suffering from moderate-to-severe pain and in need of continuous opioid treatment for an extended period of time. CRL Issued in January 2011 On January 7, 2011, Endo Pharma announced that the FDA had issued a CRL for the painkiller. Even though the US regulatory body declined to approve the new formulation of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Launches Generic Levaquin</title>
		<link>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444</link>
		<comments>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:46:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77444</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Johnson &#38; Johnson’s (JNJ) antibiotic drug, Levaquin, in the US. Data from IMS Health reveal that the branded product recorded sales of $1.1 billion in the trailing twelve months ending March 2011. Only recently Dr. Reddy’s announced the launch of three other generic products in the US. The company launched the generic versions of Pfizer Inc.’s (PFE) anti-depressant, Effexor XR, Eisai Co. Ltd.’s Alzheimer’s treatment, Aricept, and Novartis AG’s (NVS) breast cancer treatment, Femara. We believe that the launches of all these generic drugs will bring in additional revenues for Dr. Reddy’s Global Generics segment, which recorded sales of $1.2 billion in fiscal 2011 (ending March 2011), reflecting a sharp year-over-year increase of 10%. Interestingly we note ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer&#8217;s Lyrica Holds Promise</title>
		<link>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400</link>
		<comments>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77400</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently presented positive top-line data on its blockbuster drug, Lyrica. Pfizer said that Lyrica met the primary endpoint in a study that was being conducted in patients with chronic central neuropathic pain following traumatic spinal cord injury. Patients participating in the double-blind, placebo-controlled, parallel group, multi-center study (Study A0081107) were randomized to receive Lyrica or placebo. Initial results showed that Lyrica demonstrated positive efficacy in reducing central neuropathic pain following spinal cord injury compared to placebo. Pfizer will analyze the data further. Pfizer has been working on expanding Lyrica’s label for additional indications. Lyrica has experienced a very strong ramp since its introduction. Total Lyrica sales in 2010 were $3.0 billion. The product is approved in 110 countries and regions for indications like diabetic nerve pain, pain ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Boosts Immunology Pipeline</title>
		<link>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422</link>
		<comments>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422#comments</comments>
		<pubDate>Fri, 24 Jun 2011 22:04:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77422</guid>
		<description><![CDATA[Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently being evaluated in phase II studies for RA and psoriasis. Moreover, the candidate’s potential to be used for other immune-related diseases is being evaluated in preclinical studies. BT-061 could be differentiated from other anti-CD4 antibodies as it does not cause depletion of CD4 positive T-cells which would lead to weakened immune responses. Terms of the Deal Per the terms of the agreement, BT-061 will be co-promoted by Abbott Labs and Biotest in the five major European markets: Germany, France, United Kingdom, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XLE) Stock Market News for June 24, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/06/24/xle-stock-market-news-for-june-24-2011-market-news/77389</link>
		<comments>http://www.stockbloghub.com/2011/06/24/xle-stock-market-news-for-june-24-2011-market-news/77389#comments</comments>
		<pubDate>Fri, 24 Jun 2011 20:37:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[Energy Select Sector SPDR]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[HES]]></category>
		<category><![CDATA[Hess Corporation]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[PBR]]></category>
		<category><![CDATA[Petroleo Brasileiro]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[XLE]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77389</guid>
		<description><![CDATA[On Thursday, markets rebounded from session lows as Greece agreed to implement a five-year austerity plan. Markets were dragged lower early in the day after a drop in oil prices. However, news from the domestic front was discouraging with disappointing economic reports on initial claims and home sales. The Dow Jones Industrial Average (DJIA) declined 0.5% to close at 12,050.00. The Standard &#38; Poor 500 (S&#38;P 500) shed 0.3% to finish at 1,283.50. However, the Nasdaq Composite Index climbed up 0.7% to close at 2,686.75. The fear-gauge CBOE Volatility Index (VIX) traded above 19. On the New York Stock Exchange, Amex and Nasdaq, consolidated volumes were 8.31 billion shares, compared with the daily average of 7.57 billion. On the NYSE, 13 stocks moved up for every 17 stocks in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/xle-stock-market-news-for-june-24-2011-market-news/77389/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug</title>
		<link>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318</link>
		<comments>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:18:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77318</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation (AF). Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US and other countries. Top-line results from the double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin with respect to the combined outcome of stroke and systemic embolism. Data further revealed that Eliquis was superior to warfarin with respect to effectiveness and major bleeding. Bristol-Myers and Pfizer intend to seek approval from the US Food and Drug Administration (FDA) and also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Acura Pharmaceuticals Win FDA Approval for Oxecta</title>
		<link>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271</link>
		<comments>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:12:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77271</guid>
		<description><![CDATA[Pfizer Inc. (PFE) and partner Acura Pharmaceuticals Inc. (ACUR) recently received US Food and Drug Administration (FDA) approval for their pain treatment, Oxecta (oxycodone). Oxecta (formerly known as Acurox) gained approval for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta became a part of Pfizer’s portfolio following its acquisition of King Pharma earlier this year. Oxecta has been developed under an agreement for the licensing, development, and commercialization of immediate release (IR) pain medicines utilizing Acura&#8217;s Aversion (abuse-deterrent) technology. The abuse-deterrent technology has been designed to discourage opioid abuse and misuse through common ways of tampering. Oxecta’s approval triggers a $20 million milestone payment to Acura from Pfizer. Remoxy Action Date Round the Corner Pfizer has another important ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug on Track</title>
		<link>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061</link>
		<comments>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:02:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77061</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently reported positive results from a late-stage trial, REVIVE-RP (TA-303), on avanafil. The study evaluated the safety and efficacy of avanafil in the treatment of erectile dysfunction (ED) following bilateral, nerve-sparing, radical prostatectomy. The candidate met all the primary endpoints of the study, which included improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvement in the International Index of Erectile Function (IIEF). Additionally, the data showed that successful intercourse was achieved within 15 minutes of taking avanafil. On average, the patients who enrolled for the study were 58 years old, 19 months past their prostatectomy surgery dates and diagnosed with severe ED. The patients were given 100 mg or 200 mg of avanafil or placebo and were ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

